Advisory

Choose your Partner

Both partners offer free account opening and dedicated support.

Angel One

Best for active traders

₹ 0 Account Opening Open Account →

Motilal Oswal

Best for long-term wealth

₹ 0 Account Opening Open Account →

IPO Stock Quote & Charts

₹815.35

-3.30 (-0.40%)

Open

₹816.10

Day High - Low

₹821.45 - ₹801.40

Previous Close

₹818.65

Traded Value

5,67,956.00

No. of Trades

35,314

52 Weeks High

₹1,226.80 (May 12, 2026)

52 Weeks Low

₹789.00 (Sep 30, 2025)

Updated On: Sep 11, 2026

Record Date

[.]

Entitlement Ratio

:

Open Date

[.]

Listing At

[.]

  • Issue Size (Shares)
    [.]
  • Issue Price
  • Terms of Payment
    ₹ per share payable in full at the time of application.
  • Issue Size (Amount)
    ₹1,300.00 Crores
  • Face Value
    ₹2 per share
  • Listing At
    BSE, NSE

Company Financials (Restated Consolidated)

Natco Pharma Ltd.’s revenue decreased by 9% and profit after tax (PAT) dropped by 25% between the financial year ending with March 31, 2026 and March 31, 2025.   (Amount in ₹ Crore)

Period Ended 30 Jun 2026 31 Mar 2026 31 Mar 2025
Total Income 794.40 4,375.90 4,784.00
Profit After Tax 206.50 1,418.50 1,883.40
NET Worth 9,538.50 9,221.10 7,607.00
Reserves and Surplus 9,502.70 9,185.30 7,571.20

About Natco Pharma Ltd.

Incorporated in 1981, NATCO Pharma Limited is a pharmaceutical company engaged in the research, development, manufacturing and marketing of niche and complex pharmaceutical products across domestic and international markets. The Company operates across pharmaceuticals and Crop Health Sciences, with a focus on developing affordable and differentiated healthcare solutions.

The Company’s pharmaceutical business includes Finished Dosage Formulations (FDFs) and Active Pharmaceutical Ingredients (APIs) across therapeutic areas such as oncology, gastroenterology and hepatology, neurology, infectious diseases, cardiology and diabetology. Its API business focuses on complex chemistries and specialty products, with oncology as a key area. NATCO has developed more than 75 APIs and has over three decades of experience in API development and commercialization.

NATCO also operates its Crop Health Sciences business, offering agrochemical products including insecticides, fungicides, herbicides and plant growth promoters. The Company has introduced Chlorantraniliprole-based products and pheromone-based pest management solutions, with a focus on environmentally conscious crop protection and green chemistry.

The Company has manufacturing facilities for formulations, APIs and crop health sciences, along with dedicated research and development centres. Its facilities are located across Telangana, Andhra Pradesh, Uttarakhand, Assam and Tamil Nadu and have approvals from various global regulatory authorities. NATCO markets and distributes its products in over 50 countries, including the United States, India, Canada and Brazil.

Objects of the Issue:

  • # Issue Objects
    Est Amt (₹ Cr.)
  • 1 Pre-payment or repayment of all or a portion of certain outstanding borrowings availed by the Company
    810.50
  • 2 Funding a portion of the expenditure towards research and development initiatives of the Company, including funding costs of employees in our research and development team
    110.00
  • 3 General Corporate Purposes
  • Total
    920.50

Company Contact Information

Natco Pharma Ltd.
‘NATCO House”
Road No. 2
Banjara Hills
Hyderabad, 500034

  • 914023547532
  • investors@natcopharma.co.i

Rights Issue Registrar

Kfin Technologies Ltd.

Rights Issue FAQs

The Natco Pharma Rights Issue September 2026 open and close dates are not available as of now.`

Sorry the Natco Pharma Rights Issue September 2026 timelines are not available at this time.

The price of the Natco Pharma Rights Issue September 2026 is not yet set.

The Natco Pharma Rights Issue September 2026 ratio is not yet declared.

The Natco Pharma Rights Issue September 2026 record date is not yet declared.

The issue size of Natco Pharma Rights Issue September 2026 is of [.] equity shares at aggregating up to ₹1,300.00 Crores.

The Letter of Offer for Natco Pharma Rights Issue September 2026 can be downloaded here.

You can apply for Natco Pharma Rights Issue September 2026 in two ways:

Net Banking (ASBA)
Registrar’s Website (R-WAP Facility)
Steps to apply for Natco Pharma Rights Issue September 2026 using Net Banking (ASBA)

Log in to the net banking account of your bank.
Go to the ‘IPO & Rights Issue’ section.
Check if the Natco Pharma Rights Issue September 2026 is available on the list.
Click the Apply button next to the Natco Pharma Rights Issue September 2026.
Fill and check your information.
Submit the application.
Steps to apply for Natco Pharma Rights Issue September 2026 using Registrar’s website (R-WAP)

Visit registrar’s website
Go to the ‘Rights Issue’ section
Select Natco Pharma Rights Issue September 2026 from the dropdown.
Enter Demat Account Number.
Fill the online application form.
Validate and submit the application.

Stock Broker Reviews India

2.34/5
Angel One Limited

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

2.34/5
Angel One Limited

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

2.34/5
Angel One Limited

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

2.34/5
Angel One Limited 2

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

2.34/5
Angel One Limited

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

2.34/5
Angel One Limited

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

Advertisments

Compare India's most trusted brokers side-by-side to find your perfect match.